A genome-wide association study identifies four genetic markers for hematological toxicities in cancer patients receiving gemcitabine therapy

Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer

(2010) Motofumi Tanaka et al.   CANCER

Homozygous CDA*3 is a major cause of life-threatening toxicities in gemcitabine-treated Japanese cancer patients

(2009) H Ueno et al.   BRITISH JOURNAL OF CANCER

Single Nucleotide Polymorphisms of Gemcitabine Metabolic Genes and Pancreatic Cancer Survival and Drug Toxicity

(2009) T. Okazaki et al.   CLINICAL CANCER RESEARCH

Phase II Studies of Gemcitabine and Cisplatin in Heavily and Minimally Pretreated Metastatic Breast Cancer

(2009) Helen K. Chew et al.   JOURNAL OF CLINICAL ONCOLOGY

Correlation of CDA, ERCC1, and XPD Polymorphisms with Response and Survival in Gemcitabine/Cisplatin-Treated Advanced Non-Small Cell Lung Cancer Patients

(2008) C. Tibaldi et al.   CLINICAL CANCER RESEARCH

Prognostic Factors in Japanese Patients with Advanced Pancreatic Cancer Treated with Single-agent Gemcitabine as First-line Therapy

(2008) T. Tanaka et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Palliative chemotherapy for patients with recurrent hepatocellular carcinoma after liver transplantation

(2008) Jeong-Ok Lee et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Distribution of gemcitabine pathway genotypes in ethnic Asians and their association with outcome in non-small cell lung cancer patients

(2008) Ross A. Soo et al.   LUNG CANCER